Analysis of the Potential Savings of Rivaroxaban Events Versus Vitamin K Antagonists Events

Bayer

Status: Completed

Conditions: Atrial Fibrillation

Treatments: Drug: Rivaroxaban (Xarelto, BAY59-7939); Drug: Vitamin K antagonists (VKAs)

Study type: Observational

Funder types: Industry

Identifiers

NCT03462446

18231

Details and patient eligibility

About

The main objective of this project is to evaluate savings in direct costs as regards the use of rivaroxaban versus vitamin K antagonists (VKAs) in routine clinical practice using data from three cohorts of patients receiving VKAs or rivaroxaban in Spain, including the time in therapeutic range (TTR) values of the same and the incidence of events in the first year following diagnosis.

Enrollment: 249 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Older than 18 years
• Diagnosis of non-valvular AF (ICD code 427.31)
• Pharmacological treatment with VKAs or rivaroxaban following diagnosis

Exclusion criteria

Trial design

249 participants in 2 patient groups

Treatment group with Rivaroxaban

Description:

Patients treated with Rivaroxaban

Treatment:

Drug: Rivaroxaban (Xarelto, BAY59-7939)

Control group with VKAs

Description:

Patients treated with VKAs. This control group will be subsequently divided based on the TTR value in the last 6 months (below 65% and above 65%).

Treatment:

Drug: Vitamin K antagonists (VKAs)